Log in to save to my catalogue

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell l...

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell l...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1874438895

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

About this item

Full title

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2017-03, Vol.389 (10072), p.917-929

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase ( ALK )-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients. Methods This randomised, open-label, phase 3 study in untreated patients with st...

Alternative Titles

Full title

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1874438895

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1874438895

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(17)30123-X

How to access this item